Role of TSG101 in cancer

Frontiers in Bioscience

Volumn 18, Issue 1, 2013, Pages 279-288

  Jiang, Yun ^a   Ou, Yu ^a   Cheng, Xiaodong ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cancer; Cell proliferation; Cytokinesis; Endosomal sorting; Review; TSG101; Tumorigenesis; Ubiquitination

Indexed keywords

DNA BINDING PROTEIN; ESCRT PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

ANIMAL; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; MOUSE; OVARY TUMOR; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANIMALS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS;

MLCS; MLOWN;

EID: 84878798656     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4099     Document Type: Review

References (97)

1. A. Maucuer, J. H. Camonis, and A. Sobel: Stathmin interaction with a putative kinase and coiled-coil-forming protein domains. Proc Natl Acad Sci U S A 92, 3100-3104 (1995)
2. L. Li and S. N. Cohen: Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85, 319-329 (1996)
3. L. Li, X. Li, U. Francke, and S. N. Cohen: The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 88, 143-154 (1997)
4. P. Steiner, D. M. Barnes, W. H. Harris, and R. A. Weinberg: Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer. Nat Genet 16, 332-333 (1997)
5. Q. Zhong, C. F. Chen, Y. Chen, P. L. Chen, and W. H. Lee: Identification of cellular TSG101 protein in multiple human breast cancer cell lines. Cancer Res 57, 4225-4228 (1997)
6. C. F. Xu, J. Greenman, and E. Solomon: Truncated TSG101 transcripts are present in peripheral blood from both familial breast cancer patients and controls. Eur J Cancer 34, 1077-1080 (1998)
7. M. Hampl, J. Hampl, J. Plaschke, G. Fitze, G. Schackert, H. D. Saeger, and H. K. Schackert: Evidence that TSG101 aberrant transcripts are PCR artifacts. Biochem Biophys Res Commun 248, 753-760 (1998)
8. K. U. Wagner, P. Dierisseau, E. B. Rucker, III, G. W. Robinson, and L. Hennighausen: Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene 17, 2761-2770 (1998)
9. L. Li, U. Francke, and S. N. Cohen: Retraction. The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 93, following-(1998)
10. E. V. Koonin and R. A. Abagyan: TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat Genet 16, 330-331 (1997)
11. C. P. Ponting, Y. D. Cai, and P. Bork: The breast cancer gene product TSG101: a regulator of ubiquitination? J Mol Med 75, 467-469 (1997)
12. O. Pornillos, S. L. Alam, R. L. Rich, D. G. Myszka, D. R. Davis, and W. I. Sundquist: Structure and functional interactions of the Tsg101 UEV domain. EMBO J 21, 2397-2406 (2002)
13. A. Palencia, J. C. Martinez, P. L. Mateo, I. Luque, and A. Camara-Artigas: Structure of human TSG101 UEV domain. Acta Crystallogr D Biol Crystallogr 62, 458-464 (2006)
14. W. I. Sundquist, H. L. Schubert, B. N. Kelly, G. C. Hill, J. M. Holton, and C. P. Hill: Ubiquitin recognition by the human TSG101 protein. Mol Cell 13, 783-789 (2004)
15. X. Ren, D. P. Kloer, Y. C. Kim, R. Ghirlando, L. F. Saidi, G. Hummer, and J. H. Hurley: Hybrid structural model of the complete human ESCRT-0 complex. Structure 17, 406-416 (2009)
16. O. Pornillos, S. L. Alam, D. R. Davis, and W. I. Sundquist: Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nat Struct Biol 9, 812-817 (2002)
17. Y. J. Im, L. Kuo, X. Ren, P. V. Burgos, X. Z. Zhao, F. Liu, T. R. Burke, Jr., J. S. Bonifacino, E. O. Freed, and J. H. Hurley: Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction. Structure 18, 1536-1547 (2010)
18. S. Burgdorf, P. Leister, and K. H. Scheidtmann: TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. J Biol Chem 279, 17524-17534 (2004)
19. N. Elia, R. Sougrat, T. A. Spurlin, J. H. Hurley, and J. Lippincott-Schwartz: Dynamics of endosomal sorting complex required for transport (ESCRT) machinery during cytokinesis and its role in abscission. Proc Natl Acad Sci U S A 108, 4846-4851 (2011)
20. E. Morita, V. Sandrin, H. Y. Chung, S. G. Morham, S. P. Gygi, C. K. Rodesch, and W. I. Sundquist: Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. EMBO J 26, 4215-4227 (2007)
21. H. H. Lee, N. Elia, R. Ghirlando, J. Lippincott-Schwartz, and J. H. Hurley: Midbody targeting of the ESCRT machinery by a noncanonical coiled coil in CEP55. Science 322, 576-580 (2008)
22. M. Fabbro, B. B. Zhou, M. Takahashi, B. Sarcevic, P. Lal, M. E. Graham, B. G. Gabrielli, P. J. Robinson, E. A. Nigg, Y. Ono, and K. K. Khanna: Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis. Dev Cell 9, 477-488 (2005)
23. K. Katoh, H. Suzuki, Y. Terasawa, T. Mizuno, J. Yasuda, H. Shibata, and M. Maki: The penta-EF-hand protein ALG-2 interacts directly with the ESCRT-I component TSG101, and Ca2+-dependently co-localizes to aberrant endosomes with dominant-negative AAA ATPase SKD1/Vps4B. Biochem J 391, 677-685 (2005)
24. H. Suzuki, M. Kawasaki, T. Inuzuka, M. Okumura, T. Kakiuchi, H. Shibata, S. Wakatsuki, and M. Maki: Structural basis for Ca2+ -dependent formation of ALG-2/Alix peptide complex: Ca2+/EF3-driven arginine switch mechanism. Structure 16, 1562-1573 (2008)
25. M. S. Kostelansky, C. Schluter, Y. Y. Tam, S. Lee, R. Ghirlando, B. Beach, E. Conibear, and J. H. Hurley: Molecular architecture and functional model of the complete yeast ESCRT-I heterotetramer. Cell 129, 485-498 (2007)
26. M. Watanabe, Y. Yanagi, Y. Masuhiro, T. Yano, H. Yoshikawa, J. Yanagisawa, and S. Kato: A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem Biophys Res Commun 245, 900-905 (1998)
27. R. Muromoto, K. Sugiyama, T. Yamamoto, K. Oritani, K. Shimoda, and T. Matsuda: Physical and functional interactions between Daxx and TSG101. Biochem Biophys Res Commun 316, 827-833 (2004)
28. M. Ferrer, S. Lopez-Borges, and P. A. Lazo: Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines. Oncogene 18, 2253-2259 (1999)
29. M. Ferrer, S. Hernandez, E. Campo, and P. A. Lazo: Loss of the TSG101 leucine zipper domain in aggressive non-Hodgkin's lymphomas. Leukemia 14, 2014-2016 (2000)
30. H. Teo, D. J. Gill, J. Sun, O. Perisic, D. B. Veprintsev, Y. Vallis, S. D. Emr, and R. L. Williams: ESCRT-I core and ESCRT-II GLUE domain structures reveal role for GLUE in linking to ESCRT-I and membranes. Cell 125, 99-111 (2006)
31. M. S. Kostelansky, J. Sun, S. Lee, J. Kim, R. Ghirlando, A. Hierro, S. D. Emr, and J. H. Hurley: Structural and functional organization of the ESCRT-I trafficking complex. Cell 125, 113-126 (2006)
32. G. H. Feng, C. J. Lih, and S. N. Cohen: TSG101 protein steady-state level is regulated posttranslationally by an evolutionarily conserved COOH-terminal sequence. Cancer Res 60, 1736-1741 (2000)
33. B. McDonald and J. Martin-Serrano: Regulation of Tsg101 expression by the steadiness box: a role of Tsg101-associated ligase. Mol Biol Cell 19, 754-763 (2008)
34. I. Amit, L. Yakir, M. Katz, Y. Zwang, M. D. Marmor, A. Citri, K. Shtiegman, I. Alroy, S. Tuvia, Y. Reiss, E. Roubini, M. Cohen, R. Wides, E. Bacharach, U. Schubert, and Y. Yarden: Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev 18, 1737-1752 (2004)
35. B. Y. Kim, J. A. Olzmann, G. S. Barsh, L. S. Chin, and L. Li: Spongiform neurodegeneration-associated E3 ligase Mahogunin ubiquitylates TSG101 and regulates endosomal trafficking. Mol Biol Cell 18, 1129-1142 (2007)
36. R. Winqvist, A. Mannermaa, M. Alavaikko, G. Blanco, P. J. Taskinen, H. Kiviniemi, I. Newsham, and W. Cavenee: Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors. Cancer Res 53, 4486-4488 (1993)
37. A. Krempler, M. D. Henry, A. A. Triplett, and K. U. Wagner: Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death. J Biol Chem 277, 43216-43223 (2002)
38. K. U. Wagner, A. Krempler, Y. Qi, K. Park, M. D. Henry, A. A. Triplett, G. Riedlinger, E. B. Rucker III, and L. Hennighausen: Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 23, 150-162 (2003)
39. M. J. Carstens, A. Krempler, A. A. Triplett, Lohuizen M. Van, and K. U. Wagner: Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J Biol Chem 279, 35984-35994 (2004)
40. Y. F. Lo, T. C. Chen, S. C. Chen, and C. C. Chao: Aberrant expression of TSG101 in Taiwan Chinese breast cancer. Breast Cancer Res Treat 60, 259-266 (2000)
41. K. B. Oh, M. J. Stanton, W. W. West, G. L. Todd, and K. U. Wagner: Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oncogene 26, 5950-5959 (2007)
42. G. Zhu, L. Reynolds, T. Crnogorac-Jurcevic, C. E. Gillett, E. A. Dublin, J. F. Marshall, D. Barnes, C. D'Arrigo, P. O. Van Trappen, N. R. Lemoine, and I. R. Hart: Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene 22, 3742-3748 (2003)
43. G. Zhu, R. Gilchrist, N. Borley, H. W. Chng, M. Morgan, J. F. Marshall, R. S. Camplejohn, G. H. Muir, and I. R. Hart: Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer 109, 541-547 (2004)
44. Y. Zhang, M. Song, Z. S. Cui, C. Y. Li, X. X. Xue, M. Yu, Y. Lu, S. Y. Zhang, E. H. Wang, and Y. Y. Wen: Down-regulation of TSG101 by small interfering RNA inhibits the proliferation of breast cancer cells through the MAPK/ERK signal pathway. Histol Histopathol 26, 87-94 (2011)
45. K. H. Lu, J. N. Weitzel, S. Kodali, W. R. Welch, R. S. Berkowitz, and S. C. Mok: A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res 57, 387-390 (1997)
46. S. A. Gayther, P. Barski, S. J. Batley, L. Li, K. A. de Foy, S. N. Cohen, B. A. Ponder, and C. Caldas: Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 15, 2119-2126 (1997)
47. M. E. Carney, G. L. Maxwell, J. M. Lancaster, C. Gumbs, J. Marks, A. Berchuck, and P. A. Futreal: Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. J Soc Gynecol Investig 5, 281-285 (1998)
48. V. Balz, H. B. Prisack, H. Bier, and H. Bojar: Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. Cancer Genet Cytogenet 138, 120-127 (2002)
49. N. A. Bennett, R. A. Pattillo, R. S. Lin, C. Y. Hsieh, T. Murphy, and D. Lyn: TSG101 expression in gynecological tumors: relationship to cyclin D1, cyclin E, p53 and p16 proteins. Cell Mol Biol (Noisy -le-grand) 47, 1187-1193 (2001)
50. T. W. Young, F. C. Mei, D. G. Rosen, G. Yang, N. Li, J. Liu, and X. Cheng: Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol Cell Proteomics 6, 294-304 (2007)
51. X. Cheng, T. W. Young, and F. C. Mei: Proteomics analyses of ovarian cancer using genetically defined human ovarian cancer models. Front Biosci 12, 5166-5174 (2007)
52. T. W. Young, D. G. Rosen, F. C. Mei, N. Li, J. Liu, X. F. Wang, and X. Cheng: Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin Cancer Res 13, 3848-3854 (2007)
53. B. B. Patel, Y. A. He, X. M. Li, A. Frolov, L. Vanderveer, C. Slater, R. J. Schilder, Mehren M. von, A. K. Godwin, and A. T. Yeung: Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 5, 137-149 (2008)
54. F. X. Bosch, M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, and K. V. Shah: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87, 796-802 (1995)
55. J. M. Walboomers, M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189, 12-19 (1999)
56. E. S. Srivatsan, B. C. Misra, M. Venugopalan, and S. P. Wilczynski: Loss of heterozygosity for alleles on chromosome II in cervical carcinoma. Am J Hum Genet 49, 868-877 (1991)
57. A. B. Mitra, V. V. Murty, R. G. Li, M. Pratap, U. K. Luthra, and R. S. Chaganti: Allelotype analysis of cervical carcinoma. Cancer Res 54, 4481-4487 (1994)
58. R. Klaes, M. Kloor, F. Willeke, P. Melsheimer, Doeberitz M. von Knebel, and R. Ridder: Significant increase of a specific variant TSG101 transcript during the progression of cervical neoplasia. Eur J Cancer 35, 733-737 (1999)
59. J. G. Chang, T. H. Su, H. J. Wei, J. C. Wang, Y. J. Chen, C. P. Chang, and C. J. Jeng: Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers. Br J Cancer 79, 445-450 (1999)
60. J. D. O'Boyle, M. L. Proctor, K. M. Fong, W. M. Lin, D. S. Miller, and C. Y. Muller: Role of TSG101 in uterine cervix cancer. Gynecol Oncol 75, 401-405 (1999)
61. T. H. Su, J. G. Chang, L. I. Perng, C. P. Chang, H. J. Wei, N. M. Wang, and C. H. Tsai: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer. Gynecol Oncol 76, 193-199 (2000)
62. C. P. Matthews, K. Shera, N. Kiviat, and J. K. McDougall: Expression of truncated FHIT transcripts in cervical cancers and in normal human cells. Oncogene 20, 4665-4675 (2001)
63. J. Broniarczyk, A. K. Olejnik-Schmidt, M. W. Luczak, M. T. Schmidt, M. Dabrowski, A. Jozefiak, W. Kedzia, A. Kwasniewska, and A. Gozdzicka-Jozefiak: Analysis of expression and structure of the TSG101 gene in cervical cancer cells. Int J Mol Med 25, 777-783 (2010)
64. A. Duenas-Gonzalez, M. Lizano, M. Candelaria, L. Cetina, C. Arce, and E. Cervera: Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer 4, 38-(2005)
65. Z. Sun, J. Pan, G. Bubley, and S. P. Balk: Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene 15, 3121-3125 (1997)
66. A. P. Stubbs, P. D. Abel, M. Golding, G. Bhangal, Q. Wang, J. Waxman, G. W. Stamp, and E. N. Lalani: Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. Am J Pathol 154, 1335-1343 (1999)
67. Z. Sun, J. Pan, W. X. Hope, S. N. Cohen, and S. P. Balk: Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer 86, 689-696 (1999)
68. A. Llorente, Deurs B. van, and K. Sandvig: Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells. Eur J Cell Biol 86, 405-415 (2007)
69. G. Ronquist and B. O. Nilsson: The Janus-faced nature of prostasomes: their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis 7, 21-31 (2004)
70. A. Larsson, G. Ronquist, C. Wulfing, E. Eltze, O. Bettendorf, L. Carlsson, B. O. Nilsson, and A. Semjonow: Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 24, 195-200 (2006)
71. A. A. Babiker, G. Ronquist, B. Nilsson, and K. N. Ekdahl: Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin. Prostate 66, 675-686 (2006)
72. B. D. Lehmann, M. S. Paine, A. M. Brooks, J. A. McCubrey, R. H. Renegar, R. Wang, and D. M. Terrian: Senescence-associated exosome release from human prostate cancer cells. Cancer Res 68, 7864-7871 (2008)
73. B. Trink, S. I. Pai, S. L. Spunt, V. Raman, P. Cairns, J. Jen, E. Gabrielson, S. Sukumar, and D. Sidransky: Absence of TSG101 transcript abnormalities in human cancers. Oncogene 16, 2815-2818 (1998)
74. Y. Oh, M. L. Proctor, Y. H. Fan, L. K. Su, W. K. Hong, K. M. Fong, Y. S. Sekido, A. F. Gazdar, J. D. Minna, and L. Mao: TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene 17, 1141-1148 (1998)
75. F. Liu, Y. Yu, Y. Jin, and S. Fu: TSG101, identified by screening a cancer cDNA library and soft agar assay, promotes cell proliferation in human lung cancer. Mol Biol Rep 37, 2829-2838 (2010)
76. C. Cai, D. Zhang, P. Lu, Y. Gao, and J. Chang: [Expression and its significance of TSG101 in lung cancer tissue and lung cancer cell lines.]. Zhongguo Fei Ai Za Zhi 11, 172-177 (2008)
77. P. Lu, D. Zhang, Y. Gao, and C. Hu: [Expression and significance of TSG101, P21 and P300/CBP in squamous cell carcinoma and adenocarcinoma of the lung.]. Zhongguo Fei Ai Za Zhi 10, 197-202 (2007)
78. J. Chang, P. Lu, C. Cai, F. Li, Z. Zhong, and D. Zhang: [The Relationship between TSG101 Protein and Notch3 Receptor in Lung Cancer.]. Zhongguo Fei Ai Za Zhi 12, 111-116 (2009)
79. M. Babst, G. Odorizzi, E. J. Estepa, and S. D. Emr: Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 1, 248-258 (2000)
80. J. E. Garrus, U. K. von Schwedler, O. W. Pornillos, S. G. Morham, K. H. Zavitz, H. E. Wang, D. A. Wettstein, K. M. Stray, M. Cote, R. L. Rich, D. G. Myszka, and W. I. Sundquist: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107, 55-65 (2001)
81. Q. Lu, L. W. Hope, M. Brasch, C. Reinhard, and S. N. Cohen: TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc Natl Acad Sci U S A 100, 7626-7631 (2003)
82. K. G. Bache, A. Brech, A. Mehlum, and H. Stenmark: Hrs regulates multivesicular body formation via ESCRT recruitment to endosomes. J Cell Biol 162, 435-442 (2003)
83. M. Watanabe, Y. Yanagi, Y. Masuhiro, T. Yano, H. Yoshikawa, J. Yanagisawa, and S. Kato: A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem Biophys Res Commun 245, 900-905 (1998)
84. A. B. Hittelman, D. Burakov, J. A. Iniguez-Lluhi, L. P. Freedman, and M. J. Garabedian: Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 18, 5380-5388 (1999)
85. Q. Zhong, Y. Chen, D. Jones, and W. H. Lee: Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 58, 2699-2702 (1998)
86. W. Xie, L. Li, and S. N. Cohen: Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc Natl Acad Sci U S A 95, 1595-1600 (1998)
87. J. Ruland, C. Sirard, A. Elia, D. MacPherson, A. Wakeham, L. Li, J. L. de la Pompa, S. N. Cohen, and T. W. Mak: p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc Natl Acad Sci U S A 98, 1859-1864 (2001)
88. C. P. Ponting, Y. D. Cai, and P. Bork: The breast cancer gene product TSG101: a regulator of ubiquitination? J Mol Med (Berl) 75, 467-469 (1997)
89. E. V. Koonin and R. A. Abagyan: TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat Genet 16, 330-331 (1997)
90. J. G. Carlton and J. Martin-Serrano: Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery. Science 316, 1908-1912 (2007)
91. Y. Yanagida-Ishizaki, T. Takei, R. Ishizaki, H. Imakagura, S. Takahashi, H. W. Shin, Y. Katoh, and K. Nakayama: Recruitment of Tom1L1/Srcasm to endosomes and the midbody by Tsg101. Cell Struct Funct 33, 91-100 (2008)
92. X. R. Ma, U. H. Edmund Sim, B. Pauline, L. Patricia, and J. Rahman: Overexpression of WNT2 and TSG101 genes in colorectal carcinoma. Trop Biomed 25, 46-57 (2008)
93. N. Koon, R. Schneider-Stock, M. Sarlomo-Rikala, J. Lasota, M. Smolkin, G. Petroni, A. Zaika, C. Boltze, F. Meyer, L. Andersson, S. Knuutila, M. Miettinen, and W. El-Rifai: Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53, 235-240 (2004)
94. R. T. Liu, C. C. Huang, H. L. You, F. F. Chou, C. C. Hu, F. P. Chao, C. M. Chen, and J. T. Cheng: Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21, 4830-4837 (2002)
95. S. F. Hsu, Y. G. Goan, H. Y. Tsai, Y. R. Lin, R. T. Liu, and J. T. Cheng: An upstream regulatory element confers orientation-independent enhancement of the TSG101 promoter activity in transformed cells. Mol Biol Rep 39, 517-525 (2012)
96. D. C. Liu, Z. L. Yang, and S. Jiang: Identification of PEG10 and TSG101 as Carcinogenesis, Progression, and Poor-Prognosis Related Biomarkers for Gallbladder Adenocarcinoma. Pathol Oncol Res (2011)
97. Y. Zhao, H. You, F. Liu, H. An, Y. Shi, Q. Yu, and D. Fan: Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett 185, 211-218 (2002)